Biotechnology company Lusaris Therapeutics – which has a lead programme focusing on DMT for treatment-resistant depression – has launched with its Series A financing of US$60...
On November 8, 2022, Colorado citizens will be casting their vote on the Natural Medicine Health Act 2022 which proposes to decriminalise and regulate the use...
Enosis, OVID and the MIND Foundation are launching an in-clinic pilot offering of psychedelic-augmented psychotherapy that will leverage Virtual Reality (VR) technology.
Verywell Mind has carried out a survey, revealing that one in three Americans who are currently in therapy are willing to try psychedelics to help with...
A researcher at Cornell University is using optical microscopy and other tools to map the brain’s neural response to psychedelics.
Awakn’s wholly-owned subsidiary, Awakn Oslo AS, has entered into a debt financing agreement with TD Veen AS, a family-owned, Norwegian investment company and current shareholder of...
In this article, Cristian Cortes, Psych-K health and wellbeing facilitator, discusses the indigenous use of plant medicines, emphasising that he believes they must be treated with...
Beckley Psytech has entered into a definitive agreement to acquire clinical-stage life science company, Eleusis Therapeutics Limited, in an all-equity transaction.
Small Pharma has had its second United States patent granted by the United States Patent Office.
Silo Wellness has confirmed it has acquired Dyscovry Science – a Toronto-based biotechnology company focused on biosynthetic manufacturing of psilocybin and its derivatives, targeting irritable bowel...